International Urology and Nephrology 33: 529–531, 2001. © 2002 Kluwer Academic Publishers. Printed in the Netherlands. 529 Analyses of 98 seminoma cases: A review article Metin Güden, Cüneyt Ulutin & Serdar Göktas . Department of Radiation Oncology and Urology Gülhane Military Medical Academy and School of Medicine, Ankara, Turkey Abstract. 98 Patients with seminoma were treated at Clinic of Radiation Oncology of Gülhane Military Medicine Academy between the years 1974–1995. All cases were undergone orchiectomy. The median age of the patients whom were staged respectively 76%, 17%, 7% according to AJCC system, stage I, stage II and stage III was 28 (20– 58). While 87 patients were undergone only radiotherapy, 11 patients with advanced stage had taken chemotherapy with radiotherapy. In 52 months of median follow up duration, 5 year disease free survival rates were 98.6%, 93.3%, 25% and 94.5% for stage I, stage II, stage III and all stages respectively. As a result, we can propose that the seminoma is a disease with good results in oncology. In our view detailed staging and new treatment approaches in advanced disease will achieve better results in the future. Key words: Radiotherapy, Seminoma Introduction Germ cell tumours of the testes have been seen very rarely and they appeared to be at the rate of 1% of neoplasms in men [1, 2, 3]. About 5500–6000 new cases are detected in the U.S. every year [1, 2, 4]. Occurrence rate in the society is 0.04% [2, 4, 5]. It occurs in the white population at the rate of 0.037% and in the black 0.009% whom live in U.S. [7]. Due to its seldom appearance, this tumour becomes a very important oncologic disease. It is the mostly seen carcinoma of the young male between the age of 15– 35 [1, 6]. Bilateral occurrence rate is 2–3% for the germ cell tumours of the testes and if it occurs, it is usually seminoma [4, 5]. Cryptorchidism is one of the most important etiologic factors [1, 8, 9]. Males with cryptorchidism have 10–40 times higher risk of getting tumour than the normal population [1, 2]. A history of undescending testes can be detected at about 10% in testicular neoplasm [7]. Testicular feminization syndrome increases the risk of involve- ment 40 times as much the normal population [1]. The other etiologic factors are orchitis, testicular trauma, irradiation, genetic mutations respectively. Seminoma makes up 40–50% percent of the testic- ular cancers [2]. Subtypes of seminoma are classified as classic, anaplastic, and spermatic at the occurrence rate of 85%, 10%, 5% respectively. Most presenting symptoms of the patients are listed according to their frequency: mass, testicular pain, epididimitis, gyneco- mastia, infertility and back pain. Material and methods This evaluation of the patients with histologically proven pure seminoma includes 98 cases who were staged according to the Royal Mardsen staging system between 1974 and 1995 in the Department of Radi- ation Oncology, Gülhane Military Medicine Academy. 74 cases out of 98 were Stage I (76%), 17 Stage II (17%), and 7 Stage III (7%). At the beginning of the treatment mean age of the patients was 28 (ranged 20 to 58). All 98 cases were undergone transinguinal orchiectomy. After the operation, patients were evaluated again by history, clinical examination, biochemistry, lung x-ray, abdominal ultrasonography, computerised thorax and abdominal tomogrophy. The four of the cases had histories of undescending testicle. In 55 cases localisation of the tumour was on the right side while forty cases was on the left side. However, in three cases there were bilateral tumours unfortunately.